Grant: Project Grant
Université Laval
$130,000.00
Development and validation of a cell-based assay to identify over-immunosuppression in kidney transplant recipients
EF 2018-19
Résumé
Immunosuppression is essential for the treatment of patients with auto-immune kidney disease and kidney transplant recipients. Unfortunately, patients taking immunosuppressants may experience unwanted side effects. Currently, all patients are prescribed immunosuppressants in a "one size fits all" fashion, because it is difficult to determine which patients will experience unwanted side effects. In order to individualize treatment regimens, we need a test capable of evaluating individual patient's immune function.
We recently developed an assay based on live peripheral blood cells called monocytes. To measure the ability of the immune system to respond to a foreign aggression, we cultured these cells with peptides of the Epstein-Barr virus and assessed the response by measuring the secretion of the cytokine TNF-alpha. This cell subset and this cytokine were selected based on extensive preliminary studies in a cohort of kidney recipients who were followed-up with repeated blood samples over 2 years post transplantation. We have now validated these preliminary results in remaining samples of a biobank collected for general purposes. Moreover, we have developed a second step of the assay, based on the assessment of B cells in the peripheral blood. Combined, the two step of the assay seem to predict over-immunosuppression with a high predictive value.
What we will do now is to provide conclusive evidence of the validity of the test in a multicenter study. Because the blood collection time points will be specifically designed for the purpose of this study, we will be able to precisely examine the immune response following changes of immunosuppressant doses, be it for rejection, infection or cancer. The results of this study will provide definitive support to the conduct of an interventional trial testing this assay in the real-life setting.
Programme
Project Grant
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
400837
Name
De Serres Sacha
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Clinical
Prcname2
Clinical Investigation - C: Digestive, Endocrine and Excretory Systems
Projecttitle
Development and validation of a cell-based assay to identify over-immunosuppression in kidney transplant recipients
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$130,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Immunosuppression; Nephrology; Over-Immunosuppression; Transplantation
Abstract
Immunosuppression is essential for the treatment of patients with auto-immune kidney disease and kidney transplant recipients. Unfortunately, patients taking immunosuppressants may experience unwanted side effects. Currently, all patients are prescribed immunosuppressants in a "one size fits all" fashion, because it is difficult to determine which patients will experience unwanted side effects. In order to individualize treatment regimens, we need a test capable of evaluating individual patient's immune function.
We recently developed an assay based on live peripheral blood cells called monocytes. To measure the ability of the immune system to respond to a foreign aggression, we cultured these cells with peptides of the Epstein-Barr virus and assessed the response by measuring the secretion of the cytokine TNF-alpha. This cell subset and this cytokine were selected based on extensive preliminary studies in a cohort of kidney recipients who were followed-up with repeated blood samples over 2 years post transplantation. We have now validated these preliminary results in remaining samples of a biobank collected for general purposes. Moreover, we have developed a second step of the assay, based on the assessment of B cells in the peripheral blood. Combined, the two step of the assay seem to predict over-immunosuppression with a high predictive value.
What we will do now is to provide conclusive evidence of the validity of the test in a multicenter study. Because the blood collection time points will be specifically designed for the purpose of this study, we will be able to precisely examine the immune response following changes of immunosuppressant doses, be it for rejection, infection or cancer. The results of this study will provide definitive support to the conduct of an interventional trial testing this assay in the real-life setting.
Competitiondate
201903
Approvedterm2
4 yrs 0 mth
Pinamesdelim
De Serres, Sacha
Approvedterm
4 ans 0 mois
Cihrcontribution2
~ $130,000~ $0~